^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer

    Related cancers:
    1m
    A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=27 --> 13
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12
    |
    Idylla™ KRAS Mutation Test
    |
    cisplatin • carboplatin • Lumakras (sotorasib) • pemetrexed
    1m
    Impact of Thyroid Transcription Factor-1 Expression on Outcomes of Platinum-Based Chemoimmunotherapy in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer. (PubMed, Thorac Cancer)
    Platinum/PEM/Pembro may be a therapeutic option for TTF-1-negative non-sq NSCLC with good PS and adenocarcinoma histology, although careful management of irAE is required.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1)
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    1m
    Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer. (PubMed, Adv Ther)
    STK11 mutations with KEAP1 or KRAS co-mutations are associated with significantly worse survival outcomes in mNSCLC compared with patients without these co-mutations. These findings underscore the urgent need for targeted therapies to improve prognosis in this high-risk population.
    Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • STK11 mutation • KEAP1 mutation
    1m
    ARTEMIDE-Lung03: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (clinicaltrials.gov)
    P3, N=878, Recruiting, AstraZeneca | Trial completion date: Mar 2030 --> Nov 2030 | Trial primary completion date: May 2029 --> Nov 2030
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • EGFR L861Q • ROS1 rearrangement • EGFR G719X • EGFR S768I • EGFR L858R + EGFR exon 19 deletion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)
    1m
    Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial. (PubMed, JTO Clin Res Rep)
    Teliso-V monotherapy 1.9 mg/kg elicited durable responses, irrespective of the type of previous therapy received, and maintained a manageable safety profile in patients with c-Met protein overexpressing EGFR wild-type, nonsquamous NSCLC. NCT03539536.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR wild-type • MET overexpression
    |
    Emrelis (telisotuzumab vedotin-tllv)
    1m
    Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=500, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | N=155 --> 500 | Trial completion date: Apr 2029 --> Jun 2031 | Trial primary completion date: Apr 2027 --> Jun 2031
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed
    1m
    Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) (clinicaltrials.gov)
    P1, N=120, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer. (PubMed, Mol Ther Oncol)
    AGTR1 is predominantly expressed in CAFs and is suggestive of a correlation with TGF-β-related immunosuppressive features in NSCLC. The combination of ARB with chemo-immunotherapy may enhance therapeutic efficacy through targeting that axis in CAFs, specifically in non-Sq NSCLC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
    1m
    XYN-Bev MPE: Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion (clinicaltrials.gov)
    P=N/A, N=308, Not yet recruiting, Shanghai Chest Hospital
    New trial
    |
    Avastin (bevacizumab)
    1m
    A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=570, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010
    2ms
    A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, Shandong Cancer Hospital and Institute
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR positive
    |
    Idafang (ivonescimab)
    2ms
    SKB264 Plus Goleirex in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study (clinicaltrials.gov)
    P2, N=43, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Jiataile (sacituzumab tirumotecan)